Anti-Therapeutic Action: cardiovascular disease

Biodegradation of the endocrine-disrupting compound bisphenol F by Sphingobium yanoikuyae DN12

mycolabadmin

Scientists discovered a bacterium called Sphingobium yanoikuyae that can break down bisphenol F (BPF), a toxic chemical used in plastics and coatings. The bacterium uses three special enzymes working together like a molecular assembly line to safely degrade BPF into harmless byproducts. This discovery could lead to better methods for cleaning up polluted water and soil contaminated with BPF and similar harmful chemicals.

Read More »

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

mycolabadmin

This study tests whether psilocybin (a psychedelic compound) combined with intensive therapy can help treat chronic PTSD better than therapy alone. Fifteen patients with PTSD will receive one dose of psilocybin alongside 12 therapy sessions completed over a single week. Researchers will track feasibility, safety, symptom improvements, and use wearable devices to monitor physiological changes. The results will help determine whether larger trials should test this innovative combination therapy.

Read More »
Scroll to Top